Taylor and coworkers explored a group of 73 BRAF-mutant melanoma patients who received adjuvant therapy with anti-PD1 agents and who experienced recurrence: all these patients underwent local therapy, and a group of these patients (61 patients) received a “second adjuvant” therapy with BRAF/MEK inhibitors, while a second group (12 patients) had no additional therapy [68]. This evidence concerns the gene MAP2K7 and melanoma.